Physician profile
Erin Key
NPI 1811441660
$2,797.17
in general payments reported to CMS, 2019-2025
27 companies · $722 in 2025
The $722 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $337 · 2023: $609 · 2024: $587 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $583.09 | 2021-2025 | General - Pain Management, General - Therapies, Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $348.62 | 2021-2024 | Ztlido |
| Ibsa Pharma INC. | $286.23 | 2021-2025 | Licart, Tirosint, Tirosint |
| Forte Bio-Pharma LLC | $256.72 | 2024 | Prolate, Nalocet |
| Globus Medical, INC. | $175.78 | 2025 | Senza |
| Azurity Pharmaceuticals, INC. | $147.03 | 2023-2025 | Horizant, Horizant |
| Collegium Pharmaceutical, INC. | $134.23 | 2021-2025 | Xtampza, Belbuca |
| Idorsia Pharmaceuticals US INC | $100.49 | 2023-2024 | Quviviq |
| Biodelivery Sciences International, INC. | $74.42 | 2021 | |
| Arbor Pharmaceuticals, INC. | $71.98 | 2021-2022 | |
| Medtronic, INC. | $67.26 | 2022-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $66.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.33 | 2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $55.14 | 2025 | |
| Nevro Corp. | $49.84 | 2023-2024 | Senza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $46.07 | 2022-2023 | Durolane |
| Lilly USA, LLC | $41.05 | 2021-2022 | |
| Pfizer INC. | $38.30 | 2021-2024 | |
| Curonix LLC | $36.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Averitas Pharma INC. | $26.75 | 2025 | Qutenza |
| Biotronik Nro, INC. | $24.74 | 2025 | Prospera |
| Pacira Pharmaceuticals Incorporated | $20.92 | 2025 | Zilretta, Iovera |
| Abbvie INC. | $19.68 | 2021 | |
| Stimwave Technologies Incorporated | $15.98 | 2021 | |
| Protega Pharmaceutials INC | $15.91 | 2023 | Roxybond |
| Horizon Therapeutics Plc | $15.08 | 2022 | |
| Avanos Medical | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.